Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q1 2025 Earnings Report

Immuneering logo
$5.11 -0.25 (-4.66%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$5.11 0.00 (-0.10%)
As of 07/10/2026 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q1 2025
Date
5/5/2025
Time
Before Market Opens
Conference Call Date
Monday, May 5, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Immuneering's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Immuneering's Q1 2025 Press ReleasePress Release
(8-K)
Immuneering's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Immuneering Earnings Headlines

Immuneering Corp - Ordinary Shares Class A
July 11 at 2:44 PM  |  money.usnews.comhttps://money.usnews.com/investing/stocks/imrx-immuneering-corp-ordinary-shares-class-a
Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Moderate Buy" by Analysts
July 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30871522
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon Musk has been quietly doubling down on it, even attempting to deploy it during his time at DOGE before being shut down. Investing legend Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - has spent six years analyzing this sector he calls 'W.T.E.' He believes it could be 90 times bigger than AI and 1,900 times bigger than Bitcoin.tc pixel
July 12 at 1:00 AM  |  Brownstone Research (Ad)
Immuneering Appoints Veteran Biotech Leader as New CFO
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immuneering-appoints-veteran-biotech-leader-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311702/0/en/immuneering-appoints-andrew-gengos-as-chief-financial-officer.html
Immuneering Shareholders Approve Directors and Auditor at Meeting
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immuneering-shareholders-approve-directors-and-auditor-at-meeting?utm_source=marketbeat.com&utm_medium=referral
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools